An independent two-stage DCF analysis by a frontier AI model.
Edwards Lifesciences operates at the cutting edge of medical technology. By pioneering the transcatheter aortic valve replacement (TAVR) procedure, EW revolutionized the treatment of severe aortic stenosis, allowing patients to avoid open-heart surgery. This innovation established a massive, wide-moat business characterized by exceptional gross margins and intense brand loyalty among cardiovascular specialists. The recent spinoff of its Critical Care division underscores management's commitment to focusing purely on the most lucrative, high-growth segments of structural heart disease.
While the TAVR market in the US is maturing, the runway for international expansion remains long. More importantly, EW is aggressively pursuing the next frontier: therapies for the mitral and tricuspid valves (TMTT). If EW can replicate even a fraction of its TAVR success in these new, complex areas, the current valuation presents a compelling entry point. Our DCF model suggests the stock is currently undervalued, offering a margin of safety for long-term investors willing to bet on EW's continued clinical innovation.
An 11% free cash flow growth rate is supported by the continued global expansion of the core TAVR business and the launch of new, high-margin therapies in the TMTT space (mitral and tricuspid). The recent spinoff of the lower-margin Critical Care unit further boosts the overall growth and margin profile.
An 8.0% discount rate reflects EW's strong competitive position, wide moat, and robust balance sheet, balanced against the inherent risks of clinical trial failures and intense competition in the medical device sector.
A 3.0% terminal growth rate assumes that the aging global population and the ongoing shift toward minimally invasive structural heart procedures will support long-term growth slightly above the general economy.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 2.0% | $118.25 | $94.60 | $78.83 | $67.57 | $59.12 |
| 2.5% | $135.14 | $105.11 | $86.00 | $72.77 | $63.07 |
| 3.0% | $157.67 | $118.25 | $94.60 | $78.83 | $67.57 |
| 3.5% | $189.20 | $135.14 | $105.11 | $86.00 | $72.77 |
| 4.0% | $236.50 | $157.67 | $118.25 | $94.60 | $78.83 |
■ Undervalued vs current price ■ Overvalued vs current price
Our DCF model projects that the market is underestimating the long-term cash flow potential of EW's newer mitral and tricuspid valve therapies, focusing too heavily on slowing growth rates in the mature US TAVR market.
By spinning off the slower-growing, lower-margin Critical Care business, EW becomes a 'pure play' on structural heart innovation. This improves the company's overall margin profile and focuses R&D entirely on its highest-return opportunities.
The primary risks include clinical trial setbacks for its pipeline devices, increased competition in the TAVR space driving down prices, and the slower-than-expected commercial adoption of its new TMTT products.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.